Herantis Pharma to Host a Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout
Herantis Pharma Plc (“Herantis” or “Company”) will be hosting a webinar to share more details on CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months (https://herantis.com/press_releases/herantis-pharma-plc-announces-cdnf-phase-i-ii-study-met-primary-endpoints-of-safety-and-tolerability-at-12-months/).
Herantis Pharma Plc
Company release September 4, 2020 at 9:00 AM Eastern European Summer Time
Event Details:
CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months
Date and Time: September 15, 2020 at 15:00 – 16:00 CET
Presenters: Craig Cook CEO, Antti Vuolanto COO, Henri Huttunen CSO
The webinar will commence with a presentation by the Company, followed by a live Q&A session.
Webinar login and access details will be released on September 11, 2020.
For more information, please contact:
Julie Silber/Gabriela Urquilla
JG-IR
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
About CDNF
Cerebral Dopamine Neurotrophic Factor (CDNF) is a promising innovative drug candidate for the treatment of neurodegenerative diseases. This unique compound is a member of a novel family of unconventional neurotrophic factors which is structurally and mechanistically very distinct from all known neurotrophic factors. Specifically, CDNF acts via a multimodal mechanism that involves modulation of endoplasmic reticulum (ER) stress, a-synuclein aggregation and toxicity and reduced neuroinflammation. CDNF is patented internationally by Herantis.
In preclinical studies it has definitively been shown to be safe and effective. In particular, it protects and regenerates dopamine-generating cells in the midbrain, suggesting potential for disease modification of Parkinson’s disease. It has shown efficacy in both motor and non-motor symptoms in rodent and primate models of Parkinson’s disease.
CDNF has entered the clinic where its profile is being evaluated for safety and efficacy. A Phase I-II study was successfully completed which has established safety of the product and preliminary indications of efficacy in patients.
About Parkinson’s disease
Parkinson’s disease (PD) is a slowly progressing, incurable neurodegenerative disease caused by the loss of dopaminergic neurons in the midbrain. Common first symptoms of the disease include tremors, rigidity, and slowness of movement. While the motor symptoms can be treated with medication, the progression of the disease cannot be prevented. The benefits of medication may be lost with disease progression or their side effects can become unmanageable. The progressing disease is also associated with non-motor symptoms such as sleep problems, depression, and anxiety, which are not alleviated by current Parkinson’s drugs. It is estimated that 7-10 million people worldwide suffer from Parkinson’s disease.
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.